Linked Life Data

2009180

Source:http://linkedlifedata.com/resource/pubmed/id/2009180

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-5-8
pubmed:abstractText
The possibility that verapamil might increase the sensibility of colorectal carcinomas to doxorubicin was studied in 24 patients without previous cytotoxic chemotherapy. The treatment started with oral verapamil, which was escalated up to the individual maximum tolerable dose (defined by prolongation of P-Q in ECG, fall in blood pressure, or dizziness). The median maximum tolerable dose was 600 mg (range 320-1,440 mg). During continued verapamil administration the patients then got weekly infusions of doxorubicin, 25 mg/m2. The median number of doxorubicin courses was 8 (range 2-22). Among 21 patients evaluable for response and toxicity two partial remissions occurred but no complete remission. The study did not indicate enhanced cardiac, hematological or non-hematological toxicity from the combined treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0284-186X
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-6
pubmed:dateRevised
2009-5-12
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial.
pubmed:affiliation
Department of Oncology, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
pubmed:publicationType
Journal Article, Clinical Trial